Innate and Sobi Activate Lacutamab Partnership

Company Innate Pharma and Sobi Event Type Partnership Closing Platform Anti-KIR3DL2 Monoclonal Antibody (Lacutamab) Indication Cutaneous T-Cell Lymphoma (Sézary Syndrome, Mycosis Fungoides) Summary Innate Pharma and Sobi completed the closing conditions for their lacutamab partnership on September 16. Closing triggers a $75 million payment to…